BioSniper
PDUFA Date

PDUFA Date: lorundrostat

December 22, 2026
Company
Mineralys Therapeutics, Inc. (MLYS)
Drug
lorundrostat
Indication
adult patients with hypertension in combination with other antihypertensive drugs had been accepted

Other upcoming events for MLYS

Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundro
Dec 1, 2026

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
MLYS OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle